Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 9, 1996, Pages 2178-2182

  Larsen, Robert A ^a   Bauer, Madeline ^a   Weiner, Jonathan M ^a   Diamond, Deann M ^a   Leal, Maryann E ^a   Ding, James C ^a   Rinaldi, Michael G ^b   Graybill, J Richard ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FUNGAL MENINGITIS; FUNGICIDAL ACTIVITY; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029793057     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.9.2178     Document Type: Article

References (24)

1. Allendoerfer, R., A. J. Marquis, M. G. Rinaldi, and J. R. Graybill. 1991. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob. Agents Chemother. 35:726-729.
2. Bennett, J. E., W. E. Dismukes, R. J. Duma, G. Medoff, M. A. Sande, H. Gallis, et al. 1979. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N. Engl. J. Med. 301:126-131.
3. Berry, A. J., M. G. Rinaldi, and J. R. Graybill. 1992. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob. Agents Chemother. 36:690-692.
4. Box, G. E. P., and N. R. Draper. 1987. Empirical model-building and response surfaces. J. Wiley & Sons, New York.
5. Cleveland, W. S. 1993. Visualizing data. Hobart, Summit, N.J.
6. Cleveland, W. S., E. Grosse, and W. M. Shyu. 1991. Local regression models, p. 309-376. In J. M. Chambers and T. Hastie (ed.), Statistical models in S. Chapman and Hall, New York.
7. Greenwood, M. 1926. The natural duration of cancer. In Reports of Public Health and Medical Subjects, vol. 33. Her Majesty's Stationery Office, London.
8. Harrington, D. P., and T. R. Fleming. 1982. A class of rank test procedures for censored survival data. Biometrika 69:553-566.
9. Hoaglin, D. C., F. Mosteller, and J. W. Tukey. 1983. Understanding robust and exploratory data analysis. J. Wiley & Sons, New York.
10. Kaplan, G., and P. Meier. 1958. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457-481.
11. Larsen, R. A., S. A. Bozzette, B. E. Jones, D. Haghighat, M. A. Leal, et al. 1994. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 19:741-745.
12. Larsen, R. A., M. E. Leal, and L. S. Chan. 1990. Fluconazole compared with amphotericin B plus flucytosine for the treatment of cryptococcal meningitis: a prospective randomized trial in patients with AIDS. Ann. Intern. Med. 113:183-187.
13. Link, C. L. 1984. Confidence intervals for the survival function using Cox's proportional hazards model with covariates. Biometrics 40:601-610.
14. Martin, D. S. 1958. An experimental design in combination chemotherapy. Ann. N. Y. Acad. Sci. 76:926-929.
15. MathSoft. 1994. S-PLUS trellis displays, version 1.0. MathSoft, Inc., Seattle.
16. Milefchik, E., M. Leal, R. Haubrich, D. Haghighat, S. Bozzette, and R. Larsen. 1993. High dose fluconazole with and without flucytosine for cryptococcal meningitis in persons with AIDS. In Program and Abstracts of the 9th International Conference on AIDS, 7 to 11 June, Berlin.
17. Nguyen, M. H., F. Barchiesi, D. A. McGough, V. L. Yu, and M. G. Rinaldi. 1995. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob. Agents Chemother. 39:1691-1695.
18. Rinaldi, M. Personal communication.
19. Saag, M. S., W. G. Powderly, G. A. Cloud, et al. 1992. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N. Engl. J. Med. 326:83-89.
20. Shadomy, S., G. Wagner, A. Espinel-Ingroff, and B. Davis. 1975. In vitro studies with combinations of S-fluorocytosine and amphotericin B. Antimicrob. Agents Chemother. 28:117-121.
21. Stamm, A. M., R. B. Diasio, W. E. Dismukes, S. Shadomy, G. A. Cloud, et al., and Additional Members of the National Institute of Allergy and Infectious Diseases Mycoses Study Group. 1987. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am. J. Med. 83:236-241.
22. Statistical Sciences, Inc. 1994. S-PLUS for Windows version 3.2 supplement. MathSoft, Inc., Seattle.
23. Velez, J. D., R. Allendoerfer, M. Luther, M. G. Rinaldi, and J. R. Graybill. 1993. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J. Infect. Dis. 168:508-510.
24. Venables, W. N., and B. D. Ripley. 1994. Modern applied statistics with S-Plus. Springer-Verlag, Inc., New York.